AnaptysBio
ANAB
127 hedge funds and large institutions have $749M invested in AnaptysBio in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 42 reducing their positions, and 9 closing their positions.
124% more call options, than puts
Call options by funds: $673K | Put options by funds: $300K
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
4% more funds holding
Funds holding: 122 → 127 (+5)
4% more capital invested
Capital invested by funds: $721M → $749M (+$28M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.91% less ownership
Funds ownership: 101.57% → 100.67% (-0.91%)
29% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$12M |
| 2 |
Blackstone Inc
New York
|
+$8.34M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.79M |
| 4 |
EP
Eversept Partners
New York
|
+$1.98M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$12M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8M |
| 3 |
Renaissance Technologies
New York
|
-$3.95M |
| 4 |
Two Sigma Advisers
New York
|
-$2.52M |
| 5 |
Morgan Stanley
New York
|
-$2.28M |
ANAB Hedge Fund Activity: Q3 2021 in Review
127 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q3 2021, worth a combined $749M — up 3.9% from $721M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ANAB positions and 9 closed out — a net gain of 6 holders — while 30 added to existing stakes and 42 trimmed.
The largest buyer was Woodline Partners, adding an estimated $12M. The largest seller was BVF Inc, cutting an estimated $12M.
- 127 institutional investors held AnaptysBio (ANAB) as of Q3 2021, up from 122 in Q2 2021.
- Funds reported $749M of AnaptysBio stock for Q3 2021, up 3.9% quarter-over-quarter.
- 15 funds opened new AnaptysBio positions in Q3 2021 and 9 closed out, a net change of +6 holders.
- The largest AnaptysBio buyer in Q3 2021 was Woodline Partners, an estimated $12M added.
- The largest AnaptysBio seller in Q3 2021 was BVF Inc, an estimated $12M sold.
Based on aggregated 13F filings for Q3 2021.